Global Oligonucleotide Therapeutics Market Overview And Scope:
Global Oligonucleotide Therapeutics Market Size was estimated at USD 4303.22 million in 2022 and is projected to reach USD 10963.39 million by 2028, exhibiting a CAGR of 16.87% during the forecast period.
The Global Oligonucleotide Therapeutics Market Report 2025 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Oligonucleotide Therapeutics utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2025 and 2032. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
Top Key Players Mentioned Are: Biogen, Sarepta Therapeutics, Jazz Pharmaceuticals, Bausch and Lomb, Alnylam Pharmaceuticals, Dynavax Technologies, Kastle therapeutics, Akcea Therapeutics
Global Oligonucleotide Therapeutics Market Segmentation
By Type, Oligonucleotide Therapeutics market has been segmented into:Antisense Oligonucleotide
Aptamer
Other
By Application, Oligonucleotide Therapeutics market has been segmented into:
Neuromuscular Diseases
ATTR
Hepatic VOD
Other
Regional Analysis:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Oligonucleotide Therapeutics market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Oligonucleotide Therapeutics market.
Top Key Players Covered in Oligonucleotide Therapeutics market are:
Biogen
Sarepta Therapeutics
Jazz Pharmaceuticals
Bausch and Lomb
Alnylam Pharmaceuticals
Dynavax Technologies
Kastle therapeutics
Akcea Therapeutics
Objective to buy this Report:
1. Oligonucleotide Therapeutics analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Oligonucleotide Therapeutics market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Oligonucleotide Therapeutics Market by Type
5.1 Oligonucleotide Therapeutics Market Overview Snapshot and Growth Engine
5.2 Oligonucleotide Therapeutics Market Overview
5.3 Antisense Oligonucleotide
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Antisense Oligonucleotide: Geographic Segmentation
5.4 Aptamer
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Aptamer: Geographic Segmentation
5.5 Other
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Other: Geographic Segmentation
Chapter 6: Oligonucleotide Therapeutics Market by Application
6.1 Oligonucleotide Therapeutics Market Overview Snapshot and Growth Engine
6.2 Oligonucleotide Therapeutics Market Overview
6.3 Neuromuscular Diseases
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Neuromuscular Diseases: Geographic Segmentation
6.4 ATTR
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 ATTR: Geographic Segmentation
6.5 Hepatic VOD
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Hepatic VOD: Geographic Segmentation
6.6 Other
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size (2017-2032F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Other: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Oligonucleotide Therapeutics Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Oligonucleotide Therapeutics Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Oligonucleotide Therapeutics Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 BIOGEN
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 SAREPTA THERAPEUTICS
7.4 JAZZ PHARMACEUTICALS
7.5 BAUSCH AND LOMB
7.6 ALNYLAM PHARMACEUTICALS
7.7 DYNAVAX TECHNOLOGIES
7.8 KASTLE THERAPEUTICS
7.9 AKCEA THERAPEUTICS
Chapter 8: Global Oligonucleotide Therapeutics Market Analysis, Insights and Forecast, 2017-2032
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Antisense Oligonucleotide
8.2.2 Aptamer
8.2.3 Other
8.3 Historic and Forecasted Market Size By Application
8.3.1 Neuromuscular Diseases
8.3.2 ATTR
8.3.3 Hepatic VOD
8.3.4 Other
Chapter 9: North America Oligonucleotide Therapeutics Market Analysis, Insights and Forecast, 2017-2032
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Antisense Oligonucleotide
9.4.2 Aptamer
9.4.3 Other
9.5 Historic and Forecasted Market Size By Application
9.5.1 Neuromuscular Diseases
9.5.2 ATTR
9.5.3 Hepatic VOD
9.5.4 Other
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Oligonucleotide Therapeutics Market Analysis, Insights and Forecast, 2017-2032
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Antisense Oligonucleotide
10.4.2 Aptamer
10.4.3 Other
10.5 Historic and Forecasted Market Size By Application
10.5.1 Neuromuscular Diseases
10.5.2 ATTR
10.5.3 Hepatic VOD
10.5.4 Other
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Oligonucleotide Therapeutics Market Analysis, Insights and Forecast, 2017-2032
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Antisense Oligonucleotide
11.4.2 Aptamer
11.4.3 Other
11.5 Historic and Forecasted Market Size By Application
11.5.1 Neuromuscular Diseases
11.5.2 ATTR
11.5.3 Hepatic VOD
11.5.4 Other
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Oligonucleotide Therapeutics Market Analysis, Insights and Forecast, 2017-2032
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Antisense Oligonucleotide
12.4.2 Aptamer
12.4.3 Other
12.5 Historic and Forecasted Market Size By Application
12.5.1 Neuromuscular Diseases
12.5.2 ATTR
12.5.3 Hepatic VOD
12.5.4 Other
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Oligonucleotide Therapeutics Market Analysis, Insights and Forecast, 2017-2032
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Antisense Oligonucleotide
13.4.2 Aptamer
13.4.3 Other
13.5 Historic and Forecasted Market Size By Application
13.5.1 Neuromuscular Diseases
13.5.2 ATTR
13.5.3 Hepatic VOD
13.5.4 Other
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Oligonucleotide Therapeutics Market Analysis, Insights and Forecast, 2017-2032
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Antisense Oligonucleotide
14.4.2 Aptamer
14.4.3 Other
14.5 Historic and Forecasted Market Size By Application
14.5.1 Neuromuscular Diseases
14.5.2 ATTR
14.5.3 Hepatic VOD
14.5.4 Other
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Oligonucleotide Therapeutics Scope:
|
Report Data
|
Oligonucleotide Therapeutics Market
|
|
Oligonucleotide Therapeutics Market Size in 2025
|
USD XX million
|
|
Oligonucleotide Therapeutics CAGR 2025 - 2032
|
XX%
|
|
Oligonucleotide Therapeutics Base Year
|
2024
|
|
Oligonucleotide Therapeutics Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Biogen, Sarepta Therapeutics, Jazz Pharmaceuticals, Bausch and Lomb, Alnylam Pharmaceuticals, Dynavax Technologies, Kastle therapeutics, Akcea Therapeutics.
|
|
Key Segments
|
By Type
Antisense Oligonucleotide
Aptamer
Other
By Applications
Neuromuscular Diseases
ATTR
Hepatic VOD
Other
|
